Interview with Boris Johnson on coronvirus vaccinations

The transcript discusses the efficacy of new vaccines against the South African variant and the adaptability of UK vaccines to new variants. It emphasizes the importance of continued vaccine development. The conversation also highlights the international effort in vaccine distribution, with the UK playing a significant role in cross-border cooperation and funding initiatives like COVAX. The Oxford AstraZeneca vaccine is noted for its cost-effective distribution, benefiting millions globally.

What is the main concern regarding the new vaccines and the South African variant?

• They are completely ineffective against it.

• They are not yet tested against it.

• They are slightly less effective against it.

• They cause severe side effects.

How are UK vaccines being developed to handle new variants?

• They are being made more affordable.

• They are being tested on more people.

• They are being adapted to deal with new variants.

• They are being distributed faster.

What is the UK's stance on vaccine supply chains?

• They are uncertain about their supply chains.

• They are confident in their supply chains.

• They are dependent on other countries for supplies.

• They are facing major supply chain issues.

What is the purpose of the COVAX initiative?

• To spread vaccines around the world.

• To develop new vaccines.

• To test vaccines in different countries.

• To reduce vaccine costs.

What is a significant feature of the Oxford AstraZeneca vaccine?

• It is distributed at cost.

• It is the most expensive vaccine.

• It is only available in the UK.

• It requires special storage conditions.